AR040031A1 - Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen - Google Patents

Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen

Info

Publication number
AR040031A1
AR040031A1 ARP030101712A ARP030101712A AR040031A1 AR 040031 A1 AR040031 A1 AR 040031A1 AR P030101712 A ARP030101712 A AR P030101712A AR P030101712 A ARP030101712 A AR P030101712A AR 040031 A1 AR040031 A1 AR 040031A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
substituted
heterocycle
hydroxy
Prior art date
Application number
ARP030101712A
Other languages
English (en)
Spanish (es)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR040031A1 publication Critical patent/AR040031A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
ARP030101712A 2002-05-20 2003-05-16 Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen AR040031A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38201402P 2002-05-20 2002-05-20

Publications (1)

Publication Number Publication Date
AR040031A1 true AR040031A1 (es) 2005-03-09

Family

ID=29584346

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101712A AR040031A1 (es) 2002-05-20 2003-05-16 Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen

Country Status (13)

Country Link
US (1) US6962915B2 (cg-RX-API-DMAC7.html)
EP (1) EP1507780B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005531584A (cg-RX-API-DMAC7.html)
AR (1) AR040031A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003241561A1 (cg-RX-API-DMAC7.html)
ES (1) ES2391948T3 (cg-RX-API-DMAC7.html)
IS (1) IS7534A (cg-RX-API-DMAC7.html)
MY (1) MY135309A (cg-RX-API-DMAC7.html)
NO (1) NO20044866L (cg-RX-API-DMAC7.html)
PE (1) PE20040512A1 (cg-RX-API-DMAC7.html)
PL (1) PL374218A1 (cg-RX-API-DMAC7.html)
TW (1) TW200400034A (cg-RX-API-DMAC7.html)
WO (1) WO2003099820A1 (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
CA2483164C (en) 2002-04-23 2011-06-07 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
AU2003221753A1 (en) 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1543009A4 (en) * 2002-08-02 2007-08-08 Bristol Myers Squibb Co Pyrrolotriazine KINASE INHIBITORS
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
AU2004212435A1 (en) 2003-02-05 2004-08-26 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine kinase inhibitors
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
JP2007517052A (ja) * 2003-12-23 2007-06-28 ノバルティス アクチエンゲゼルシャフト 二環式ヘテロ環式ｐ−３８キナーゼ阻害剤
CA2557268A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them
MXPA06009462A (es) 2004-02-27 2007-03-15 Hoffmann La Roche Derivados pirazolo heteroaril fusionados.
AU2005219525B2 (en) 2004-02-27 2011-08-18 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
US7067659B2 (en) * 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
TW200600513A (en) * 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
ATE517901T1 (de) 2004-09-06 2011-08-15 Bayer Schering Pharma Ag Pyrazolopyrimidine als hemmer der proteinkinase b (akt)
GB0425035D0 (en) * 2004-11-12 2004-12-15 Novartis Ag Organic compounds
GB0427604D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
CA2594422A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
AU2006205851A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
GB0507575D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US20060264431A1 (en) * 2005-05-11 2006-11-23 Array Biopharma Inc. P38 inhibitors and methods of use thereof
AU2006283935A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag Fused pyrazole as p38 MAP kinase inhibitors
EP1919913A2 (en) * 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
MX2008002588A (es) 2005-08-25 2008-03-18 Hoffmann La Roche Inhibidores de p38-map-cinasa y los metodos para utilizarlos.
GB0522880D0 (en) * 2005-11-09 2005-12-21 Glaxo Group Ltd Novel compounds
GB0524436D0 (en) * 2005-11-30 2006-01-11 Novartis Ag Organic compounds
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
KR20080110783A (ko) 2006-03-07 2008-12-19 어레이 바이오파마 인크. 헤테로바이시클릭 피라졸 화합물 및 사용 방법
US8933089B2 (en) 2006-03-30 2015-01-13 Janssen R & D Ireland HIV inhibiting 5-amido substituted pyrimidines
WO2007139778A2 (en) * 2006-05-22 2007-12-06 University Of Virginia Patent Foundation Rhamnose substituents of sl0101 and therapeutic uses thereof
RU2009118254A (ru) 2006-10-16 2010-11-27 Новартис АГ (CH) Фенилацетамиды в качестве ингибиторов протеинкиназ
CN101600714B (zh) 2006-11-10 2013-08-21 百时美施贵宝公司 吡咯并吡啶激酶抑制剂
CA2672719A1 (en) * 2006-12-19 2008-06-26 F. Hoffmann-La Roche Ag Pyrazolo [3, 4 -d] pyrimidine p38 map kinase inhibitors
WO2009023053A2 (en) * 2007-05-18 2009-02-19 University Of Virginia Patent Foundation Use of rsk inhibitors to impede intracellular pathogen infections
EA019869B1 (ru) 2007-11-28 2014-06-30 Дана Фарбер Кансер Инститьют, Инк. Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
ES2494365T3 (es) * 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
KR20110017431A (ko) * 2008-06-10 2011-02-21 아보트 러보러터리즈 신규한 트리사이클릭 화합물
WO2010011620A1 (en) * 2008-07-21 2010-01-28 Wyeth 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010059788A1 (en) 2008-11-20 2010-05-27 Genentech, Inc. Pyrazolopyridine pi3k inhibitor compounds and methods of use
CA2756871A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
TWI500620B (zh) 2009-12-01 2015-09-21 Abbvie Inc 新穎三環化合物
NZ599938A (en) * 2009-12-01 2014-08-29 Abbvie Inc Novel tricyclic compounds
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
CN103313987A (zh) * 2010-11-19 2013-09-18 弗·哈夫曼-拉罗切有限公司 吡唑并吡啶化合物、吡唑并吡啶化合物以及它们作为tyk2抑制剂的用途
TWI399205B (zh) * 2011-01-14 2013-06-21 Univ Kaohsiung Medical 茶鹼化合物之抑制骨質疏鬆症活性
EP2548878A1 (en) * 2011-07-21 2013-01-23 Laboratorios Del. Dr. Esteve, S.A. Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands
CN102746306B (zh) * 2012-07-09 2014-11-19 四川国康药业有限公司 别嘌醇类衍生物及其制备方法和用途
CN103570723B (zh) * 2012-07-27 2016-07-13 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
EA201500402A1 (ru) 2012-11-08 2016-05-31 Пфайзер Инк. Гетероароматические соединения в качестве лигандов допамина d1
CN103601722B (zh) * 2013-09-13 2016-03-02 南京华威医药科技开发有限公司 新型抗肿瘤化合物
US9957270B2 (en) 2014-03-13 2018-05-01 Agency For Science, Technology And Research Fused pyrimidine-based hydroxamate derivatives
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CA3251507A1 (en) 2015-10-16 2025-05-21 Abbvie Inc. Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11034689B2 (en) * 2016-10-26 2021-06-15 The Trustees Of Indiana University Small molecule protein arginine methyltransferase 5 (PRMT5) inhibitors and methods of treatment
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
CA3240377A1 (en) * 2021-12-08 2023-06-15 Gnanasambandam Kumaravel Bicyclic heteroarenes and methods of their use
CN117865965B (zh) * 2024-01-08 2024-06-28 贵州省天然产物研究中心 吡咯并嘧啶-4-胺和吡唑并嘧啶-4-胺衍生物及制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720674A (en) * 1970-09-02 1973-03-13 Squibb & Sons Inc 4-amino-1h-pyrazolo(3,4-d)pyrimidine derivatives
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
DK1017378T3 (da) 1997-09-23 2003-03-17 Astrazeneca Ab Amidderivater til behandling af sygdomme medieret af cytokiner
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
PL204437B1 (pl) 1999-05-21 2010-01-29 Bristol Myers Squibb Co Pochodna pirolotriazyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
JP4623483B2 (ja) 1999-08-23 2011-02-02 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有するピロロトリアジン誘導体
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
US6548509B2 (en) * 1999-10-22 2003-04-15 Neurogen Corporation 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
PL348924A1 (en) 1999-11-10 2002-06-17 Ortho Mcneil Pharm Inc Substituted 2−aryl−3−(heteroaryl)−imidazo[1,2−a
AU2001277621A1 (en) 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
ES2317923T3 (es) 2000-08-09 2009-05-01 Astrazeneca Ab Compuestos de cinolina.
AU7653601A (en) 2000-08-09 2002-02-18 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
EP1311500A2 (en) 2000-08-09 2003-05-21 AstraZeneca AB Indole, azaindole and indazole derivatives having vegf inhibiting activity
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
AU2003221753A1 (en) 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
CA2483164C (en) 2002-04-23 2011-06-07 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
NO20044866L (no) 2004-12-17
EP1507780A1 (en) 2005-02-23
AU2003241561A1 (en) 2003-12-12
PE20040512A1 (es) 2004-08-25
ES2391948T3 (es) 2012-12-03
EP1507780B1 (en) 2012-08-22
US6962915B2 (en) 2005-11-08
WO2003099820A1 (en) 2003-12-04
MY135309A (en) 2008-03-31
EP1507780A4 (en) 2006-08-02
JP2005531584A (ja) 2005-10-20
US20040023992A1 (en) 2004-02-05
TW200400034A (en) 2004-01-01
PL374218A1 (en) 2005-10-03
IS7534A (is) 2004-11-16

Similar Documents

Publication Publication Date Title
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
AR035548A1 (es) Compuestos organicos
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
CO5631447A2 (es) Derivados de heteriarilamida benzocondesada de tieno- piridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos, y metodos pra su uso
PE20020589A1 (es) 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas
ATE512955T1 (de) Stickstoffhaltige heterozyklische derivate und medikamente die diese enthalten
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
HRP20020109B1 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
PE20010964A1 (es) Derivados de tiazolilamida
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
AR054799A1 (es) Derivados de oxindol
BR9915475A (pt) Derivados da quinolina-4-carboxamida comoantagonistas dos receptores de nk-3 e nk-2
AR032621A1 (es) Compuestos derivados de tiofeno, metodo para su preparacion, composicion farmaceutica y uso en la fabricacion de medicamentos
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR042586A1 (es) 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
BR9307580A (pt) Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano
ATE140698T1 (de) Diazotierte heterocyclische derivate aus stickstoff, substituiert durch eine biphenylgruppe, ihre herstellung, und diese enthaltende pharmazeutische zubereitungen
ES2081136T3 (es) 3-ureido-benzodiazepinonas utiles como antagonistas de cck o de gastrina.
SE0201937D0 (sv) Therapeutic agents
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
AR035230A1 (es) Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
PE20011349A1 (es) 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales

Legal Events

Date Code Title Description
FB Suspension of granting procedure